Publications

Export 43 results:
Auteur Title [ Type(Asc)] Année
Filtres: Auteur is John CS Breitner  [Enlever les filtres]
Journal Article
Breitner JCS.  2014.  What should we do if we were wrong and Alzheimer was right? Int Psychogeriatr. 26(1):3-6.
Steinberg M, Hess K, Corcoran C, Mielke MM, Norton M, Breitner JCS, Green R, Leoutsakos J, Welsh-Bohmer K, Lyketsos C et al..  2014.  Vascular risk factors and neuropsychiatric symptoms in Alzheimer's disease: the Cache County Study.. Int J Geriatr Psychiatry. 29(2):153-9.
Peterson D, Munger C, Crowley J, Corcoran C, Cruchaga C, Goate AM, Norton MC, Green RC, Munger RG, Breitner JCS et al..  2014.  Variants in PPP3R1 and MAPT are associated with more rapid functional decline in Alzheimer's disease: the Cache County Dementia Progression Study.. Alzheimers Dement. 10(3):366-71.
Dadar M, Pascoal TA, Manitsirikul S, Misquitta K, Tartaglia C, Breitner JCS, Rosa-Neto P, Carmichael O, DeCarli C, D Collins L.  2017.  Validation of a Regression Technique for Segmentation of White Matter Hyperintensities in Alzheimer's Disease.. IEEE Trans Med Imaging.
Chuang Y-F, Breitner JCS, Chiu Y-L, Khachaturian A, Hayden K, Corcoran C, Tschanz J, Norton M, Munger R, Welsh-Bohmer K et al..  2014.  Use of diuretics is associated with reduced risk of Alzheimer's disease: the Cache County Study.. Neurobiol Aging. 35(11):2429-35.
Zimmer ERigon, Leuzy A, Benedet ALessa, Breitner JCS, Gauthier S, Rosa-Neto P.  2014.  Tracking neuroinflammation in Alzheimer's disease: the role of positron emission tomography imaging.. J Neuroinflammation. 11:120.
Orban P, Madjar C, Savard M, Dansereau C, Tam A, Das S, Evans AC, Rosa-Neto P, Breitner JCS, Bellec P.  2015.  Test-retest resting-state fMRI in healthy elderly persons with a family history of Alzheimer's disease.. Sci Data. 2:150043.
Verfaillie SCJ, Binette APichet, Vachon-Presseau E, Tabrizi S, Savard M, Bellec P, Ossenkoppele R, Scheltens P, van der Flier WM, Breitner JCS et al..  2018.  Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer's Disease.. Biol Psychiatry Cogn Neurosci Neuroimaging. 3(5):463-472.
Verfaillie SCJ, Binette APichet, Vachon-Presseau E, Tabrizi S, Savard M, Bellec P, Ossenkoppele R, Scheltens P, van der Flier WM, Breitner JCS et al..  2017.  Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer’s Disease.
Colby-Milley J, Cavanagh C, Jego S, Breitner JCS, Quirion R, Adamantidis A.  2015.  Sleep-Wake Cycle Dysfunction in the TgCRND8 Mouse Model of Alzheimer's Disease: From Early to Advanced Pathological Stages.. PLoS One. 10(6):e0130177.
Tardif CL, Devenyi GA, Amaral RSC, Pelleieux S, Poirier J, Rosa-Neto P, Breitner JCS, M Chakravarty M.  2018.  Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease.. Hum Brain Mapp. 39(2):971-984.
Breitner JCS, Poirier J, Etienne PE, Leoutsakos JM.  2016.  Rationale and Structure for a New Center for Studies on Prevention of Alzheimer's Disease (StoP-AD).. J Prev Alzheimers Dis. 3(4):236-242.
Villeneuve S, Vogel JW, Gonneaud J, Binette APichet, Rosa-Neto P, Gauthier S, Bateman RJ, Fagan AM, Morris JC, Benzinger TLS et al..  2018.  Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease.. JAMA Neurol.
Zuo X-N, Anderson JS, Bellec P, Birn RM, Biswal BB, Blautzik J, Breitner JCS, Buckner RL, Calhoun VD, F Castellanos X et al..  2014.  An open science resource for establishing reliability and reproducibility in functional connectomics.. Sci Data. 1:140049.
Lafaille-Magnan M-E, Poirier J, Etienne P, Tremblay-Mercier J, Frenette J, Rosa-Neto P, Breitner JCS.  2017.  Odor identification as a biomarker of preclinical AD in older adults at risk.. Neurology. 89(4):327-335.
Breitner JCS.  2015.  Observations on DSM-5 Mild Neurocognitive Disorder vs. its predecessor, Mild Cognitive Impairment.. Acta Psychiatr Scand. 131(1):15-7.
Meyer P-F, Labonte A, Rosa-Neto P, Poirier J, Breitner JCS.  2019.  No apparent effect of naproxen on CSF markers of innate immune activation.. Ann Clin Transl Neurol. 6(6):1127-1133.
Heneka MT, Carson MJ, Khoury JEl, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM et al..  2015.  Neuroinflammation in Alzheimer's disease.. Lancet Neurol. 14(4):388-405.
Tullo S, Patel R, Devenyi GA, Salaciak A, Bedford SA, Farzin S, Wlodarski N, Tardif CL, Breitner JCS, M Chakravarty M.  2019.  MR-based age-related effects on the striatum, globus pallidus, and thalamus in healthy individuals across the adult lifespan.. Hum Brain Mapp.
Breitner JCS.  2014.  Mild cognitive impairment and progression to dementia: new findings.. Neurology. 82(4):e34-5.
Chuang Y-F, An Y, Bilgel M, Wong DF, Troncoso JC, O'Brien RJ, Breitner JCS, Ferruci L, Resnick SM, Thambisetty M.  2015.  Midlife adiposity predicts earlier onset of Alzheimer's dementia, neuropathology and presymptomatic cerebral amyloid accumulation.. Mol Psychiatry.
Meyer P-F, Tremblay-Mercier J, Leoutsakos J, Madjar C, Lafaille-Maignan M-É, Savard M, Rosa-Neto P, Poirier J, Etienne P, Breitner JCS.  2019.  INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.. Neurology. 92(18):e2070-e2080.
Cavanagh C, Tse YChung, Nguyen H-B, Krantic S, Breitner JCS, Quirion R, Wong TPan.  2016.  Inhibiting tumor necrosis factor-α before amyloidosis prevents synaptic deficits in an Alzheimer's disease model.. Neurobiol Aging. 47:41-49.
Meyer P-F, Savard M, Poirier J, Morgan D, Breitner JCS.  2019.  Hypothesis: cerebrospinal fluid protein markers suggest a pathway toward symptomatic resilience to AD pathology.. Alzheimers Dement. 15(9):1160-1171.
Tam A, Dansereau C, Iturria-Medina Y, Urchs S, Orban P, Sharmarke H, Breitner JCS, Bellec P.  2019.  A highly predictive signature of cognition and brain atrophy for progression to Alzheimer's dementia.. Gigascience. 8(5)

Pages